Clinical Evaluation of a Daily Wear Frequent Replacement Silicone Hydrogel Lens
Phase: NA
Conditions: Refractive Errors
Sponsor: Alcon Research



Page 2 of 59
Investigator Agreement:

I have read the clinical study described herein, recognize its confidentiality, and 
agree to conduct the described trial in compliance with Good Clinical Practice 
(GCP), the ethical principles contained within the Declaration of Helsinki, this 
protocol, all applicable regulatory authority regulations, and conditions of approval 
imposed by the reviewing IRB or regulatory authority.

I will supervise all testing of the device involving human subjects and ensure that 
the requirements relating to obtaining informed consent and IRB review and 
approval are met in accordance with applicable local and governmental regulations.

I have read and understand the appropriate use of the investigational product(s) as 
described in the protocol, current Investigator’s Brochure, product information, or 
other sources provided by the Sponsor.

I understand the potential risks and side effects of the investigational product(s).

I agree to maintain adequate and accurate records in accordance with government 
regulations and to make those records available for inspection.

I agree to comply with all other requirements regarding the obligations of clinical 
Investigators and all other pertinent requirements of the Sponsor and government 
agencies.

I agree to ensure that all associates, colleagues, and employees assisting in the 
conduct of the study are informed of their obligations in meeting the above 
commitments.
Have you ever been disqualified as an Investigator by any Regulatory Authority?
No        Yes
Have you ever been involved in a study or other research that was terminated?
No        Yes
If yes, please explain here:
Principal Investigator:
Signature
Date
Name and professional 
position:
Address:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 3 of 59
Table of Contents
Clinical Evaluation of a Daily Wear Frequent Replacement Silicone Hydrogel Lens ..............1
Table of Contents .......................................................................................................................3
List of Tables..............................................................................................................................5
List of Figures............................................................................................................................6
1
GLOSSARY OF TERMS ....................................................................................................7
2
LIST OF ACRONYMS AND ABBREVIATIONS ...........................................................11
3
PROTOCOL SUMMARY.................................................................................................13
5
INTRODUCTION.............................................................................................................22
5.1
Rationale and Background ................................................................................22
5.2
Purpose of the Study..........................................................................................23
5.3
Risks and Benefits.............................................................................................23
6
STUDY OBJECTIVES......................................................................................................24
6.1
Primary Objective(s) .........................................................................................24
6.2
Secondary Objective(s) .....................................................................................24
6.4
Safety Objective(s)............................................................................................24
7
INVESTIGATIONAL PLAN ............................................................................................25
7.1
Study Design .....................................................................................................25
7.4
Rationale for Choice of Control Product...........................................................26
7.5
Data Monitoring Committee..............................................................................27
8
STUDY POPULATION ....................................................................................................27
8.1
Inclusion Criteria...............................................................................................27
8.2
Exclusion Criteria..............................................................................................28
8.3
Rescreening of Subjects ....................................................................................29
9
TREATMENTS ADMINISTERED...................................................................................29
9.1
Investigational Product(s)..................................................................................29
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 4 of 59
9.3
Treatment Assignment / Randomization ...........................................................35
9.4
Treatment masking ............................................................................................35
9.5
Accountability Procedures.................................................................................37
9.6
Changes to concomitant medications, treatments/ procedures..........................38
10 STUDY PROCEDURES AND ASSESSMENTS.............................................................38
10.1
Informed Consent and Screening ......................................................................39
10.2
Description of Study Procedures and Assessments...........................................40
10.2.1
Demographics....................................................................................40
10.2.2
Medical History and Concomitant Medications................................40
10.2.3
Investigational Product Compliance..................................................40
10.2.4
Adverse Event Collection: Safety Assessment..................................40
10.2.5
Slit-Lamp Biomicroscopy: Safety Assessment .................................40
10.2.6
Device Deficiencies: Safety Assessment...........................................40
10.5
Discontinued Subjects .......................................................................................42
10.5.1
Screen Failures ..................................................................................42
10.5.2
Discontinuations................................................................................42
10.5.3
Schedule of Procedures and Assessments for Subjects Discontinued 
from Investigational Product .............................................................43
10.6
Clinical Study Termination................................................................................43
10.6.1
Follow-up of subjects after study participation has ended ................44
11 ADVERSE EVENTS AND DEVICE DEFICIENCIES ...................................................44
11.1
General Information ..........................................................................................44
11.2
Monitoring for AEs............................................................................................47
11.3
Procedures for Recording and Reporting ..........................................................47
11.5
Unmasking of the Study Treatment...................................................................50
11.6
Follow-Up of Subjects with AEs.......................................................................50
11.7
Pregnancy in the Clinical Study........................................................................50
12 ANALYSIS PLAN ............................................................................................................51
12.1
Subject Evaluability...........................................................................................51
12.2
Analysis Sets .....................................................................................................51
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 5 of 59
12.3
Demographic and Baseline Characteristics.......................................................51
12.4
Effectiveness Analyses ......................................................................................51
12.4.1
Analysis of Primary Effectiveness Endpoint(s).................................52
12.4.1.1
Statistical Hypotheses........................................................52
12.4.1.2
Analysis Methods ..............................................................52
12.5
Handling of Missing Data .................................................................................53
12.6
Safety Analyses .................................................................................................53
13 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS ...............................54
13.1
Subject Confidentiality......................................................................................54
13.2
Completion of Source Documents and Case Report Forms..............................55
13.3
Data Review and Clarifications.........................................................................56
13.4
Sponsor and Monitoring Responsibilities .........................................................56
13.5
Regulatory Documentation and Records Retention ..........................................56
13.6
Quality Assurance and Quality Control.............................................................57
14 ETHICS .............................................................................................................................57
15 REFERENCES ..................................................................................................................58
15.1
References applicable for all clinical studies ....................................................58
15.1.1
US references applicable for clinical studies.....................................58
List of Tables
Table 2–1
List of Acronyms and Abbreviations Used in This Protocol ...........................11
Table 3–1
Schedule of Study Procedures and Assessments .............................................18
Table 6–1
Primary Objective(s)........................................................................................24
Table 6–2
Safety Objective(s)...........................................................................................24
Table 9–1
Test Product .....................................................................................................30
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 6 of 59
Table 9–2
Control Product................................................................................................32
List of Figures
Figure 7-1
Flowchart of Study Visits.................................................................................26
Figure 11–1
Categorization of All AEs................................................................................44
Figure 11–2
Categorization of All SAE ...............................................................................45
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 8 of 59
Requirements for reporting Device Deficiencies in the study 
can be found in Section 11.
Enrolled Subject
Any subject who signs an informed consent form for 
participation in the study.
Interventional Clinical Trial
A research trial that prospectively assigns, whether 
randomly or not, human participants or groups of humans to 
one or more health-related interventions to evaluate the 
effects on health outcomes, and/or a research trial in which 
diagnostic or monitoring procedures beyond standard of care 
are conducted and generate outcomes for use in analysis of 
data.
Investigational Product
Is defined as a preventative (vaccine), a therapeutic (drug or 
biologic), device, diagnostic, or palliative used as a test or 
control product in a clinical trial, including a product with a 
marketing authorization when used or assembled 
(formulated or packaged) in a way different from the 
authorized form, or when used for an unauthorized 
indication, or when used to gain further information about 
the authorized form.
Malfunction
Failure of a medical device to perform in accordance with its 
intended purpose when used in accordance with the 
instructions for use or clinical investigation plan.
Non-serious Adverse Event
Adverse event that does not meet the criteria for a serious
adverse event.
Randomized Subjects
Any subject who is assigned a randomized treatment.
Serious Adverse Device 
Effect (SADE)
Adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event.
Serious Adverse Event 
(SAE)
Adverse event that led to any of the following:

Death.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 9 of 59

A serious deterioration in the health of the subject 
that either resulted in:
a. a life-threatening illness or injury.
Note: Life-threatening means that the 
individual was at immediate risk of death from 
the event as it occurred, ie, it does not include 
an event which hypothetically might have 
caused death had it occurred in a more severe 
form.
b. any potentially sight-threatening event or 
permanent impairment to a body structure or a 
body function.
c. in-patient hospitalization or prolonged 
hospitalization.
Note: Planned hospitalization for a pre-
existing condition, without serious 
deterioration in health, is not considered a 
serious adverse event. In general, 
hospitalization signifies that the individual 
remained at the hospital or emergency ward 
for observation and/or treatment (usually 
involving an overnight stay) that would not 
have been appropriate in the physician's office 
or an out-patient setting. Complications that 
occur during hospitalization are adverse 
events. If a complication prolongs 
hospitalization or fulfills any other serious 
criteria, the event is serious. When in doubt as 
to whether “hospitalization” occurred, the 
event should be considered serious.
d. a medical or surgical intervention to prevent 
a) or b). 
e. any indirect harm as a consequence of 
incorrect diagnostic test results when used 
within manufacturer’s instructions for use.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 10 of 59

Fetal distress, fetal death, or a congenital abnormality 
or birth defect.
Refer to Section 11 for additional SAEs.
Significant Non-Serious 
Adverse Event
Is a symptomatic, device-related, non-sight threatening 
adverse event that warrants discontinuation of any contact 
lens wear for greater than or equal to 2 weeks.
Refer to Section 11 for additional Significant Non-Serious 
AEs.
Unanticipated Serious 
Adverse Device Effect
Serious adverse device effect which by its nature, incidence, 
severity or outcome has not been identified in the risk 
management file.
Use Error
Act or omission of an act that results in a different medical 
device response than intended by manufacturer or expected 
by user. Note: This definition includes slips, lapses, and 
mistakes. An unexpected physiological response of the 
subject does not in itself constitute a use error.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 12 of 59
Abbreviation
Definition
SADE 
Serious adverse device effect
SiHy 
Silicone hydrogel
SOP
Standard operating procedure
US / USA
United States of America
USAN
United States Adopted Name
USV
Unscheduled visit
VA 
Visual acuity
vs
Versus 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 14 of 59
 
 
 
 
 
 
Investigational 
product type
Medical Device
Study type
Interventional
Investigational 
products
Test Product: 
 soft contact lens
Control Product: Biofinity soft contact lens
Purpose and 
rationale
The purpose of this clinical study is to demonstrate the 
performance of the investigational 
 soft contact lens 
compared to the commercially available Biofinity soft contact lens
when worn in a daily wear modality, by assessing visual acuity as 
the primary variable.
Objective(s)
The primary objective is to demonstrate safety and effectiveness of 
the 
 soft contact lens when worn for daily wear as 
compared to the Biofinity soft contact lens.
Endpoint(s)
Primary Effectiveness

Distance VA (Snellen) 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 15 of 59
 
 
 
Safety

AEs

Biomicroscopy findings

Device deficiencies
Assessment(s) 
Effectiveness

VA with study lenses (Snellen distance)
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 16 of 59
Safety

AEs

Biomicroscopy

Device deficiencies
Study Design
This will be a prospective, randomized, 
 
 controlled, double-masked, parallel-group, daily 
wear clinical study. Subject participation in the study will be 
approximately 14 weeks with approximately 3 months of exposure 
to study lenses.
Subject population
Volunteer subjects aged 18 or over who are adapted daily wear 
frequent replacement soft contact lens wearers, excluding Biofinity 
habitual wearers, have at least 3 months of soft contact lens 
wearing experience, and who wear their habitual lenses at least 
5 days per week and at least 8 hours per day. 
 
 
 
 
Key inclusion 
criteria
(See Section 8.1 for a 

Successful wear of spherical daily wear frequent 
replacement soft contact lenses for distance correction in 
both eyes during the past 3 months for a minimum of 5 days 
per week and 8 hours per day.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 17 of 59
complete list of 
inclusion criteria)

Manifest cylinder ≤ 0.75 D in each eye
Key exclusion
criteria
(See Section 8.2 for a 
complete list of 
exclusion criteria)

Wearing habitual contact lenses in an extended wear 
modality (routinely sleeping in lenses for at least 1 night per 
week) over the last 3 months prior to enrollment.

Monovision contact lens wearers

Habitually wearing Biofinity lenses
Data analysis and 
sample size 
justification
 
effectiveness and safety data will be presented separately based 
upon subject study status of Completed or Discontinued.
No formal hypotheses are formulated for the primary effectiveness 
endpoint, hence no inferential testing will be performed. 
 
 
 
 
 
Key words
 Biofinity, daily wear, 
Associated materials
CLEAR CARE Cleaning & Disinfecting Solution will be used for 
daily cleaning and disinfection. 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 22 of 59
 
 
 
 
 
 
 
5
INTRODUCTION
5.1
Rationale and Background
 
 
 
 
 
 
 
 
In this clinical study, the performance of the investigational 
 contact lens will be 
compared to the commercially available Biofinity contact lens in a parallel group design to 
demonstrate the safety and effectiveness of the 
 contact lens, worn daily 
 
as compared to Biofinity contact lens, worn daily 
 
The intended use of this contact lens is for vision correction. Therefore, the 
measurement of distance VA is planned as the primary effectiveness variable. 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 24 of 59
 
 
 
 
Refer to the IB for additional information.
6
STUDY OBJECTIVES
6.1
Primary Objective(s)
Table 6–1
Primary Objective(s)
Objective(s)
Endpoint(s)
Demonstrate safety and effectiveness of 
soft contact lens when worn for 
daily wear as compared to Biofinity soft 
contact lens.
Primary Effectiveness 

Distance VA (Snellen)
6.2
Secondary Objective(s)
Not Applicable
6.4
Safety Objective(s)
Table 6–2
Safety Objective(s)
Objective(s)
Endpoint(s)
Duty of care and evaluation of safety profile 
of the investigational products.
AEs
Biomicroscopy findings
Device deficiencies
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 28 of 59
8.2
Exclusion Criteria
Subjects fulfilling any of the following criteria are not eligible for participation in this study.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 29 of 59
11.
Wearing habitual contact lenses in an extended wear modality (routinely sleeping in 
lenses for at least 1 night per week) over the last 3 months prior to enrollment.
13.
Monovision wearers.
16.
Any habitual wear of Biofinity lenses.
Women of childbearing potential or women who are pregnant at the time of study entry are
not excluded from participation. 
 
 
 
8.3
Rescreening of Subjects
Rescreening of subjects is not allowed in this study.
9
TREATMENTS ADMINISTERED
9.1
Investigational Product(s)
Test Product(s):
 soft contact lenses
Control Product(s) 
Biofinity (comfilcon A) soft contact lenses
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 31 of 59
 
 
 

Lens Care: CLEAR CARE
 
 
 
 
 
 
Packaging 
description
Blister foil pack
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 32 of 59
Table 9–2
Control Product
Control Product(s)
Biofinity (comfilcon A) soft contact lenses (Biofinity contact lens)
(LID010221)
Manufacturer
CooperVision
Indication for Use
The intended use of this contact lens is for vision correction.
Product description 
and parameters 
available for this 
study

Material: comfilcon A

Water content: 48%

Power range: -1.00 to -6.00 D (0.25 D steps)

Base curve: 8.6 mm (target)

Diameter: 14.0 mm (target)
Formulation
Silicone Hydrogel. Additional details can be found in the Biofinity 
package insert.
Usage

Wear:
o
Daily Wear
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 34 of 59
More information on the test product can be found in the IB; information on the control 
product can be found in the Package Insert. 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 36 of 59
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 37 of 59
9.5
Accountability Procedures
It is the Investigator’s responsibility to ensure that:

All study products are accounted for and not used in any unauthorized manner

Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 38 of 59

All unused products are available for return to the Study Sponsor, as directed

Any study lenses associated with a device deficiency or with any product-related AE
(ie, ADE or SADE) are returned to the Study Sponsor for investigation, unless
otherwise directed by the Sponsor. Refer to Section 11 of this protocol for additional
information on the reporting of device deficiencies and AEs
The Investigator is responsible for proper disposition of all unused IPs at the conclusion of 
the study, 
9.6
Changes to concomitant medications, treatments/ procedures
After the subject is enrolled into the study, the Investigator must instruct the subject to notify 
the study site about:

Any new medications

Alterations in dose or dose schedules for current medications,

Any medical procedure or hospitalization that occurred or is planned

Any non-drug therapies (including physical therapy and blood transfusions).
The Investigator must document this information in the subject’s case history source 
documents.
10 STUDY PROCEDURES AND ASSESSMENTS
Subjects will be expected to attend 6 office visits, as shown below.
Visit #
Visit Type
Visit Day
Visit 1
Screening/Baseline/Randomization/Dispense
Day 1
Visit 2
Week 1 Follow-up Visit
Day 7
Visit 3
Week 2 Follow-up Visit
Day 15
Visit 4
Month 1 Follow-up Visit
Day 30
Visit 5
Month 2 Follow-up Visit
Day 60
Visit 6
Month 3 Follow-up / Exit Visit
Day 95
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 40 of 59
The Investigator or delegate must provide a copy of the signed document to the subject and 
place the original signed document in the subject’s chart, or provide documentation as 
required by local regulations.
10.2 Description of Study Procedures and Assessments
 The 
Investigator is responsible for ensuring responsibilities for all procedures and assessments are 
delegated to appropriately qualified site personnel.
10.2.1 Demographics
Obtain demographic information including age, race, ethnicity, and sex.
10.2.2 Medical History and Concomitant Medications
Collect medical history information, including information on all medications used within the 
past 30 days. Include herbal therapies, vitamins, and all over-the-counter as well as 
prescription medications. Throughout the subject’s participation, obtain information on any 
changes in medical health and/or the use of concomitant medications.
10.2.3 Investigational Product Compliance
Review subject compliance with the study lenses usage and adjunct product usage 
 
10.2.4 Adverse Event Collection: Safety Assessment
Assess and record any AEs that are observed or reported, including those associated with 
changes in concomitant medication dosing since the previous visit. Requirements for 
reporting AEs in the study can be found in Section 11.
10.2.5 Slit-Lamp Biomicroscopy: Safety Assessment
Slit-lamp examination of the cornea, iris/anterior chamber, and lens must be performed in 
both eyes before instillation of any diagnostic eye drops.
10.2.6 Device Deficiencies: Safety Assessment
Assess and record any device deficiencies that are reported or observed since the previous 
visit. Requirements for reporting device deficiencies in the study can be found in Section 11.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 41 of 59
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 42 of 59
 
 
 
  
10.5 Discontinued Subjects
10.5.1 Screen Failures
Screen failures are subjects who were excluded from the study after signing the informed 
consent, not meeting the inclusion/exclusion criteria, and prior to randomization to 
product/dispense of study product. 
The Investigator must document the reason for screen failure in the subject’s case history 
source documents.
Subject numbers must not be re-used.
10.5.2 Discontinuations
Discontinued subjects are individuals who voluntarily withdraw or are withdrawn from the 
study by the Investigator after signing the informed consent. 
Subject numbers of discontinued subjects must not be re-used.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 43 of 59
Subjects may discontinue from study or study treatment at any time for any reason. Subjects 
may also be discontinued from study treatment at any time if, in the opinion of the 
Investigator, continued treatment poses a risk to their health.
 
 
 
 
 
 
 
10.6 Clinical Study Termination
The Study Sponsor reserves the right to close the investigational site or terminate the study in 
its entirety at any time.
If the clinical study is prematurely terminated or suspended by the Study Sponsor: 

The Study Sponsor must:
o
Immediately notify the Investigator(s) and subsequently provide 
instructions for study termination.
o
Inform the Investigator and the regulatory authorities of the 
termination/suspension and the reason(s) for the termination/suspension. 

The Investigator must:
o
Promptly notify the IRB/IEC of the termination or suspension and of the 
reasons. 
o
Provide subjects with recommendations for post-study treatment options 
as needed.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 44 of 59
The Investigator may terminate the site’s participation in the study for reasonable cause.
10.6.1 Follow-up of subjects after study participation has ended 
Following this study, the subject will return to their eye care professional for their routine eye 
care.
11 ADVERSE EVENTS AND DEVICE DEFICIENCIES
11.1 General Information
An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, 
whether or not related to the investigational medical device (test article). Refer to the 
Glossary of Terms and figures below for categories of AEs and SAEs.
Figure 11–1
Categorization of All AEs
ADE
Device /
procedure-
related?
Symptomatic, 
Device-related, 
Non sight-
threatening, D/C 
Lens Wear?
Meets 
seriousness 
criteria?
SAE
All AEs
AE
Significant     
Non-Serious AE
No
No
Yes
Yes
Yes
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 46 of 59

Hypopyon

Hyphema

Neovascularization within the central 6 mm of the cornea

Permanent vision loss as defined by loss of 2 or more lines of BCVA from enrollment 
visit that fails to resolve

Uveitis (anterior, intermediate, or posterior)

Corneal abrasion affecting ≥ 50% of corneal surface area
Significant Non-Serious AE
A significant non-serious AE is a device-related, non-sight threatening AE that warrants 
discontinuation of any contact lens wear for greater than or equal to 2 weeks. In addition, the 
Investigator must report any occurrence of the following as a Significant Non-Serious 
Adverse Event:

Peripheral non-progressive non-infectious ulcers

All symptomatic corneal infiltrative events

Corneal staining score greater than or equal to Grade 3 
 

Temporary vision loss as defined by loss of 2 or more lines of BCVA from enrollment 
visit that persists for 2 or more weeks

Neovascularization score greater than or equal to Grade 2 
 
 
 
Device Deficiencies
A device deficiency is inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety, or performance. A device deficiency may or may not be 
associated with subject harm (ie, ADE or SADE); however, not all ADEs or SADEs are due 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 47 of 59
to a device deficiency. The Investigator should determine the applicable category listed in the 
Device Deficiency eCRF for the identified or suspect device deficiency and report any 
subject harm separately. Examples of device deficiencies include the following: 

Failure to meet product specifications (eg, incorrect lens power/diameter/base 
curve/color)

Lens cloudy

Lens surface/edge defect 

Torn lens during handling/in pack

Packaging deficit (eg, mislabeled product)

Suspect product contamination

Lack of performance
11.2 Monitoring for AEs
At each visit, after the subject has had the opportunity to spontaneously mention any 
problems, the Investigator should inquire about AEs by asking the standard questions:

“Have you had any health problems since your last study visit?”

“Have there been any changes in the medicines you take since your last study visit?”
 
 
 
 
 
11.3 Procedures for Recording and Reporting
AEs are collected from the time of informed consent. Any pre-existing medical conditions or 
signs/symptoms present in a subject prior to the start of the study (ie, before informed 
consent is signed) are not considered AEs in the study and should be recorded in the Medical 
History section of the eCRF.
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 48 of 59

ADEs or SAEs are documented on the Serious Adverse Event and Adverse Device 
Effect eCRF within 24 hours of the Investigator’s or site’s awareness.

Device deficiencies are documented on the Device Deficiency eCRF within 24 hours 
of the Investigator’s or site’s awareness.

A printed copy of the completed Serious Adverse Event and Adverse Device Effect 
and/or Device Deficiency eCRF must be included with product returns.

Additional relevant information after initial reporting must be entered into the eCRF as 
soon as the data become available.

Document any changes to concomitant medications on the appropriate eCRFs.

Document all relevant information from Discharge Summary, Autopsy Report, 
Certificate of Death, etc, if applicable, in narrative section of the Serious Adverse 
Event and Adverse Device Effect eCRF.
Intensity and Causality Assessments
Where appropriate, the Investigator must assess the intensity (severity) of the AE based upon 
medical judgment with consideration of any subjective symptom(s), as defined below:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 49 of 59
Intensity (Severity)
Mild
An AE is mild if the subject is aware of but can easily tolerate the sign or 
symptom.
Moderate
An AE is moderate if the sign or symptom results in discomfort significant 
enough to cause interference with the subject’s usual activities.
Severe
An AE is severe if the sign or symptom is incapacitating and results in the 
subject’s inability to work or engage in their usual activities.
For every AE in the study, the Investigator must assess the causality (Related or Not Related 
to the medical device or study procedure). An assessment of causality will also be performed 
by Study Sponsor utilizing the same definitions, as shown below:
Causality
Related
An AE classified as related may be either definitely related or possibly related 
where a direct cause and effect relationship with the medical device or study 
procedure has not been demonstrated, but there is a reasonable possibility that 
the AE was caused by the medical device or study procedure.
Not Related
An AE classified as not related may either be definitely unrelated or simply 
unlikely to be related (ie, there are other more likely causes for the AE).
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 50 of 59
11.5 Unmasking of the Study Treatment
Masked information on the identity of the assigned medical device should not be disclosed 
during the study. 
 
 
 
 
 
 
11.6 Follow-Up of Subjects with AEs
The Investigator is responsible for adequate and safe medical care of subjects during the 
study and for ensuring that appropriate medical care and relevant follow-up procedures are 
maintained after the study. 
 
 
 
 
 
 
 
 
 
11.7 Pregnancy in the Clinical Study
Women of childbearing potential or women who are pregnant at the time of study entry are 
not excluded from participation. 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 51 of 59
12 ANALYSIS PLAN
Any deviations to the analysis plan will be updated during the course of the study as part of a 
protocol amendment or will be detailed in the clinical study report.
All analyses will be conducted according to the applicable statistical analysis plan.
12.1 Subject Evaluability
Final subject evaluability must be determined prior to breaking the code for masked treatment 
(lens) assignment and locking the database, based upon the Deviations and Evaluability Plan.
12.2 Analysis Sets
Five analysis sets will be defined:
a) All Enrolled – all subjects signing the informed consent form
b) Enrolled Dispensed – subjects/eyes from All Enrolled that have been exposed to study 
lenses 
c) Enrolled Not Dispensed – subjects/eyes from All Enrolled that have not been exposed 
to study lenses 
d) Completed – Enrolled Dispensed subjects/eyes completing the study
e) Discontinued – Enrolled Dispensed subjects/eyes not complete the study
12.3 Demographic and Baseline Characteristics
Demographic information, 
 
 will be presented by lens group and overall 
 
12.4 Effectiveness Analyses
For 
 the primary 
, separate summary tables will 
be prepared, when applicable, for the Completed and the Discontinued analysis sets as 
follows:

Completed Control (eyes/subjects)

Completed Test (eyes/subjects)
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 52 of 59

Discontinued Control (eyes/subjects)

Discontinued Test (eyes/subjects)
No inferential testing will be performed on effectiveness endpoints, 
 
12.4.1 Analysis of Primary Effectiveness Endpoint(s)
The primary objective of this study is to demonstrate safety and effectiveness of 
 soft 
contact lens when worn for daily wear as compared to Biofinity soft contact lens. 
The primary effectiveness endpoint is distance VA with study lenses, collected in Snellen, for 
each eye. Conversion will be made to the logMAR scale.
12.4.1.1 Statistical Hypotheses
No hypothesis testing of the primary effectiveness endpoint is planned.
12.4.1.2 Analysis Methods
Summary statistics will be provided.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 53 of 59
 
 
 
12.5 Handling of Missing Data
All data obtained in evaluable subjects/eyes will be used. No imputation for missing values 
will be carried out.
Incidence and reasons for discontinuation by lens group will be tabulated at each visit and 
overall.
12.6 Safety Analyses
The safety endpoints are:

AEs

Biomicroscopy Findings

Device Deficiencies
There are no safety hypotheses planned in this study. The focus of the safety analysis will be 
a comprehensive descriptive assessment of occurrence of AE as well as the other listed 
parameters.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 54 of 59
Descriptive summaries (counts and percentages) for ocular and nonocular AEs will be 
presented by Medical Dictionary for Regulatory Activities Preferred Terms, for Completed 
and Discontinued sets. A listing containing details of the AEs will also be provided. 
 
 
 
 
 
 
 
13 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS
13.1 Subject Confidentiality
The Investigator must ensure that the subject’s anonymity is maintained throughout the 
course of the study. In particular, the Investigator must keep an enrollment log with 
confidential identifying information that corresponds to the subject numbers and initials of 
each study participant.
 
 
 
 
 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 55 of 59
 
 
 
 
13.2 Completion of Source Documents and Case Report Forms
The nature and location of all source documents will be identified to ensure that original data 
required to complete the CRFs exist and are accessible for verification by the site monitor, 
and all discrepancies shall be appropriately documented via the query resolution process. Site
monitors are appointed by the Study Sponsor and are independent of study site staff.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 56 of 59
13.3 Data Review and Clarifications
A review of CRF data to the subject’s source data will be completed by the site monitor to 
ensure completeness and accuracy. After the CRFs have been completed, additional data 
clarifications and/or additions may be needed as a result of the data cleaning process. Data 
clarifications are documented and are part of each subject’s CRF.
13.4 Sponsor and Monitoring Responsibilities
The Study Sponsor will designate a monitor to conduct the appropriate site visits at the 
appropriate intervals according to the study monitoring plan. The clinical investigation will 
be monitored to ensure that the rights and well-being of the subjects are protected, the 
reported data are accurate, complete, and verifiable from the source documents, and the study 
is conducted in compliance with the current approved protocol (and amendments[s], if 
applicable), with current GCP, and with applicable regulatory requirements.
The site may not screen subjects or perform the informed consent process on any subject until 
it receives a notification from an appropriate Study Sponsor representative that the site may 
commence conducting study activities. Monitoring will be conducted periodically while the 
clinical study is ongoing. Monitoring methods may include site visits, telephone, written and 
fax correspondence. Close-out visits will take place after the last visit of the last subject at the 
site.
A Coordinating Investigator may be identified by the Study Sponsor to review and endorse 
the final study report. In cases where a Coordinating Investigator is engaged, the Study 
Sponsor will select the Coordinating Investigator based upon their experience, qualifications, 
active study participation, and their willingness and availability to take on this role.
13.5 Regulatory Documentation and Records Retention
The Investigator is required to maintain up-to-date, complete regulatory documentation as 
indicated by the Study Sponsor and the Investigator’s files will be reviewed as part of the 
ongoing study monitoring. 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 57 of 59
 
 
13.6 Quality Assurance and Quality Control
The Study Sponsor will secure agreement from all involved parties to ensure direct access to 
all study related sites, source data and documents, and reports for the purpose of monitoring 
and auditing by the Study Sponsor, and inspection by domestic and foreign regulatory 
authorities. Quality control will be applied to each stage of data handling to ensure that all 
data are reliable and have been processed correctly. Agreements made by the Study Sponsor 
with the Investigator/Institution and any other parties involved in the clinical study will be 
provided in writing as part of the protocol or as a separate agreement.
14 ETHICS
 
 
 
 
 
 
The Investigator must ensure that all personnel involved in the conduct of the study are 
qualified to perform their assigned responsibilities through relevant education, training, and 
experience. The Investigator and all clinical study staff must conduct the clinical study in 
compliance with the protocol. Deviations from this protocol, regulatory requirements and/or 
GCP must be recorded and reported to the Sponsor prior to database lock. If needed, 
corrective and preventive action should be identified, implemented, and documented within 
the study records. Use of waivers to deviate from the clinical protocol is prohibited.
Before clinical study initiation, this protocol, the informed consent form, any other written 
information given to subjects, and any advertisements planned for subject recruitment must 
be approved by an IRB/IEC. 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 58 of 59
 
 
 
 
 
Voluntary informed consent must be obtained in writing from every subject and the process
shall be documented before any procedure specific to the clinical investigation is applied to 
the subject. The Investigator must have a defined process for obtaining consent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 REFERENCES
15.1 References applicable for all clinical studies

ISO 11980:2012 Ophthalmic optics - Contact lenses and contact lens care products -
Guidance for clinical investigations

ISO 14155:2011 Clinical investigation of medical devices for human subjects - Good 
clinical practice
15.1.1 US references applicable for clinical studies

21 CFR Part 11 - Electronic Records; Electronic Signatures
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

Page 59 of 59

21 CFR Part 50 - Protection of Human Subjects

21 CFR Part 56 - Institutional Review Boards

21 CFR Part 812 - Investigational Device Exemptions

21 CFR Part 54 - Financial Disclosure by Clinical Investigators

The California Bill of Rights
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019

                                                                                                                
                                                                                     
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0056233
Protocol - Clinical
22-Mar-2019